Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1
暂无分享,去创建一个
N. Fineberg | M. Pescovitz | M. Kraus | H. Gebel | C. M. Bearden | A. Agarwal | B. Book | C. A. Vieira | R. Sidner | T. Taber | A. Roggero | Anthony L. Roggero